Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial

[1]  M. Stegall,et al.  Erratum , 2013 .

[2]  B. Tönshoff,et al.  IVIG and rituximab for treatment of chronic antibody‐mediated rejection: a prospective study in paediatric renal transplantation with a 2‐year follow‐up , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  R. Alloway,et al.  Proteasome inhibitor-based therapy for antibody-mediated rejection. , 2012, Kidney international.

[4]  R. Colvin,et al.  Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  E. Schwaiger,et al.  Prevention and treatment of alloantibody‐mediated kidney transplant rejection , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  K. Lamb,et al.  Long‐Term Renal Allograft Survival in the United States: A Critical Reappraisal , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  L. Racusen,et al.  The pathology of chronic allograft dysfunction. , 2010, Kidney international. Supplement.

[9]  Sandra K. Wittmann,et al.  Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  D. Rush,et al.  Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure , 2010, Transplantation.

[11]  C. Legendre,et al.  Antibody‐Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  R. Alloway,et al.  Proteasome inhibition for antibody-mediated rejection , 2009, Current opinion in organ transplantation.

[13]  P. Halloran,et al.  De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  T. Fehr,et al.  Rituximab and Intravenous Immunoglobulin Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection , 2009, Transplantation.

[15]  P. Reinke,et al.  Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts , 2009, Transplantation.

[16]  D. Nochy,et al.  Comparison of Combination Plasmapheresis/IVIg/Anti‐CD20 Versus High‐Dose IVIg in the Treatment of Antibody‐Mediated Rejection , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  R. Holdsworth,et al.  Review article: Luminex technology for HLA antibody detection in organ transplantation , 2009, Nephrology.

[18]  B. Tönshoff,et al.  Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients , 2008, Transplantation.

[19]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  Kerstin Amann,et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.

[21]  P. Cascio,et al.  Dampening Ab responses using proteasome inhibitors following in vivo B cell activation , 2008, European journal of immunology.

[22]  M. Stegall,et al.  Two Novel Assays of Alloantibody‐Secreting Cells Demonstrating Resistance to Desensitization With IVIG and rATG , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  R. Colvin.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. , 2007, Journal of the American Society of Nephrology : JASN.

[24]  T. Larson,et al.  Assessment of Changes in Kidney Allograft Function Using Creatinine‐Based Estimates of Glomerular Filtration Rate , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  M. Müllner,et al.  Immunoadsorption in Severe C4d‐Positive Acute Kidney Allograft Rejection: A Randomized Controlled Trial , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  S. Dikman,et al.  Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. , 2005, Transplantation.

[27]  T. Larson,et al.  Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease , 2004, Annals of Internal Medicine.

[28]  J. Schold,et al.  Long‐Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies? , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  M. Fishbein,et al.  Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  S. Takemoto,et al.  All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies , 2002, Transplantation.

[31]  Markus Exner,et al.  Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.

[32]  Christopher P. Johnson,et al.  Post-transplant renal function in the first year predicts long-term kidney transplant survival. , 2002, Kidney international.

[33]  R. Colvin,et al.  Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. , 2001, Journal of the American Society of Nephrology : JASN.

[34]  R. Montgomery,et al.  PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTS , 2000, Transplantation.

[35]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[36]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .

[37]  E. Schwaiger,et al.  Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. , 2010, Clinical transplants.

[38]  D. Leeser,et al.  Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection. , 2010, Clinical transplants.

[39]  M. Everly.  A summary of bortezomib use in transplantation across 29 centers. , 2009, Clinical transplants.